Join Us at PEGS Boston 2024
PEGS Boston is taking place from May 13-17 at the Omni Hotel at the Seaport! Our team will be at Booth #23 and will also be presenting a poster titled: “Generation of a Fully Human Antibody Library and Novel Linker/Payload to Facilitate Development of Antibody-Drug Conjugates and Other Antibody-Based Therapeutics”. Poster number: C017 Date: […]
Join us at ASGCT 2024: May 7-11
Join us at ASGCT 2024 in Baltimore, MD from May 7-11, 2024! Meet us at booth #2388 and explore our 100% guaranteed service and learn how our humanized models, disease models, and pharmacology services can enhance your Cell and Gene Therapy! Attend the meeting Meet us at booth 2388! The American Society of Gene […]
Biocytogen Enters into Evaluation and Potential Licensing Agreement with BioCopy for TCR-mimic Antibodies
May 6, 2024
Beijing, China, May 6, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland. The agreement grants BioCopy access to fully […]
May 2024 Newsletter
May 3, 2024
New Animal Models Humanized Immune-Checkpoint Mice Product Catalog Number B-hXCR1 mice 112815 B-h4-1BB, Tg(hLILRB1/hLILRB4) mice 112731 B-hCD3EDG/hCD19/hBCMA mice 113343 Humanized Cytokine Mice Product Catalog Number B-hIL12RB1/hIL12RB2 mice ad 112881 B-hFXI mice 112749 B-hLTA/hTNFA/hLTB/hTNFR2/hTNFR1/hLTBR mice 113337 B-hIL22/hIL22RA1/hIL10RB mice 113344 B-hCFB/hC5 mice 113233 B-hLPA mice plus 112845 B-hPDGFD mice 111316 B-hTFF1 mice 112542 Other Humanized […]
Join Us At Immunology 2024: May 3-7
Join us at Immunology 2024 in Chicago, IL from May 3-7! Meet our team at booth #530 and discover how our humanized models, disease models, and pharmacology services can elevate your immunology oncology studies. Attend the meeting Visit Us At Booth 530! The largest annual all-immunology event worldwide, The American Association of Immunologists (AAI) annual […]
Check Out Our CD40 mAb Phase II Poster at ASCO2024!
ASCO 2024 | Biocytogen/Eucure Biopharma to Present Two Phase II Clinical Studies of CD40 Agonistic Antibody YH003 Biocytogen’s wholly owned subsidiary Eucure Biopharma today announced that the company will present two phase II clinical studies of YH003, a humanized anti-CD40 agonistic monoclonal antibody, at the American Society of Clinical Oncology (ASCO) annual meeting, taking […]
Join us at Booth D23 at BIO KOREA 2024! May 8-10
Biocytogen’s APAC business development team is excited to exhibit and host 1-on-1 meetings at BIO KOREA 2024, taking place from May 8-10, 2024 in Seoul, South Korea! Join us at booth D23 to learn more about: How our fully human antibody library and RenMice® discovery platforms can help you design your novel drugs, as well […]
Immuno-Oncology Summit Europe 2024: April 23-25
Visit Our Bispecific Antibody Poster at IO Summit Europe 2024! Biocytogen’s antibody Business Development & Licensing team is excited to attend the upcoming Immuno-Oncology Summit Europe 2024 conference, set to take place in London, UK, from April 23-25, 2024! During the event, our team will present a poster, titled “Fully human conditional agonist 4-1BB […]
Festival of Biologics USA 2024: April 15-17
Thank you to those who joined us at the Festival of Biologics USA 2024 from April 15-17 in San Diego, CA! Our Poster titled “Generation of a TAA Antibody Library to Support the Development of Antibody-Drug Conjugates (ADC)” is now available for download using the link below. Download Poster Poster Summary: Biocytogen’s antibody […]
Biocytogen’s Antibody Partner Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024
On April 7, at AACR, our therapeutic antibody collaborator Syncromune delivered an oral presentation unveiling clinical data of its SYNC-T technology for the first time! Initial clinical data of SYNC-T SV-102, which includes our clinical-stage CTLA-4 monoclonal antibody YH001 and CD40 agonistic monoclonal antibody YH003, demonstrate a very high 85% overall response rate in patients […]
